CD58 Immunobiology at a Glance

Zhang, Yalu; Liu, Qiaofei; Yang, Sen; Liao, Quan

doi:10.3389/fimmu.2021.705260

Cited by 32 publications

(29 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies found that CD58 is a glycoprotein expressed on the surface of B cells, T cells, monocytes, granulocytes and thymic epithelial cells, an important member of the immune superprotein family, and has a role in promoting cell adhesion [19]. We found that the main studies of CD58 focused mainly on hematological tumors [23][24][25]27], skin diseases [35], where CD58 plays a rather important role through different mechanisms.…”

Section: Discussionmentioning

confidence: 95%

“…Glycoprotein CD58, also known as lymphocyte functional antigen 3 (LFA-3), is a highly glycosylated, surface glycoprotein distributed at 40-70 kDa, and is a co-stimulatory receptor distributed on a wide range of human tissue cells [19]. It is expressed on the surface of B cells, T cells, monocytes, granulocytes and thymic epithelial cells.…”

Section: Introductionmentioning

confidence: 99%

“…Both CD2 and CD58 are immunoglobulins. CD2-CD58 interaction promotes important adhesion between T cells and target cells, activates T cells, and induces a series of important signaling events involved in the regulation of T cell responses regulation [19]. For CD56 + T cells, activated monocytes provide a contact-dependent factor CD58/LFA-3 and a soluble factor IL-12, both of which are essential for their in vitro expansio [22].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CD58 as a biomarker for prognosis and immune infiltration in hepatocellular carcinoma

Cai

Chen

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

BACKGROUND The glycoprotein CD58, is a co-stimulatory receptor distributed on a wide range of human tissue cells. CD2 interacts with CD58 to promote important adhesion between T cells and target cells and to induce signaling events involved in the regulation of T cell responses. However, the relevance of CD58 to the prognosis of different tumors and to tumor-infiltrating lymphocytes is unclear. RESULTS Analysis of CD58 expression through the Tumor Immune Evaluation Resource (TIMER) website and UALCAN, revealed meaningful differential expression of CD58 between hepatocellular carcinoma (LIHC) tumor tissue and normal tissue, with higher levels of CD58 expression in hepatocellular carcinoma than in normal tissue. We used Kaplan-Meier plotter and gene expression profiling interaction analysis (GEPIA) to assess the impact of CD58 on clinical prognosis and found that high CD58 expression was associated with a poorer prognosis in hepatocellular carcinoma. The correlation between CD58 and tumor immune infiltration by TIMER revealed that CD58 expression was negatively correlated with tumor purity and positively correlated with the level of immune infiltration of B cell, Neutrophil, Macrophage, Myeloid dendritic cell and T cell CD4+. Furthermore, we analyzed the correlation between CD58 expression and the gene marker sets for immune infiltration using TIMER and GEPIA and found that in hepatocellular carcinoma, the expression levels of most monocytes, TAM, M1 macrophages, M2 macrophages, dendritic cells, Th1, Th2 and Treg marker sets correlated strongly with CD58 expression in LIHC. CONCLUSION CD58 is associated with the level of immune infiltration and prognosis of B cell, Neutrophil, Macrophage, Myeloid dendritic cell, T cell CD4 + in a variety of tumors, especially in patients with hepatocellular carcinoma. In addition, CD58 expression may help regulate the expression levels of most monocytes, TAM, M1 macrophages, M2 macrophages, dendritic cells, Th1, Th2, and Treg marker groups in hepatocellular carcinoma. It is suggested that CD58 may be used as a biomarker to determine the prognosis and immune infiltration of hepatocellular carcinoma.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CD58 as a biomarker for prognosis and immune infiltration in hepatocellular carcinoma

Cai

Chen

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The minor allele of this variant associated with lower CD58 levels on Olink Explore and less MS risk. The glycoprotein CD58, also known as lymphocyte-function antigen 3 (LFA-3), is a costimulatory receptor distributed on a broad range of human tissues including cells of the immune system, making it relevant for autoimmune diseases, including MS 46 . Based on these results both platforms are likely targeting CD58 and the discrepancies observed could result from the two platforms targeting different CD58 isoforms, or multimeric versus monomeric forms.…”

Section: Supplementary Notementioning

confidence: 99%

Large-scale comparison of immunoassay- and aptamer-based plasma proteomics through genetics and disease

Eldjárn

Ferkingstad

Lund

et al. 2022

Preprint

View full text Add to dashboard Cite

High-throughput proteomics platforms measuring thousands of proteins in blood combined with genomic information have the power to bridge the gap between the genome and diseases and in that capture some of the environmental contributions to their risk and pathogenesis. Although such methods have already demonstrated their utility, the validation of their actual protein targets is lacking. Here we present a large-scale analysis of levels of proteins in plasma and protein quantitative trait loci (pQTLs) detected using the Olink Explore 1536 (1,459 immunoassays) in 47,151 European participants from the UK Biobank with 57.7 million imputed sequence variants. We compared the results with those of a large-scale SomaScan v4 study (35,559 participants and 4,907 aptamer-based assays) in order to assess and compare the qualities of these two platforms. The correlation between levels of proteins targeted by the two platforms is modest (median Spearman correlation 0.46). The vast majority of assays on the Olink Explore platform had cis pQTLs, evidence that they correctly target their intended proteins (84%), while the assays on the SomaScan v4 platform were half as likely to have cis pQTLs (38%). We also highlight novel pQTLs discovered using the Olink Explore platform, not captured by SomaScan v4, and describe their colocalization with disease-associated sequence variants as well as associations between protein levels and diseases. Our results further underscore the value of proteomics data and highlight the major differences in quality between the two most commonly used high-throughput proteomics platforms.

show abstract

“…The occurrence and development of PDAC are responsible for multi-factor and multi-step processes, such as the activation/ inactivation of oncogenes/tumor suppressor genes, tumor stem cell, gene mutation, epigenetic modification, and posttranslational regulation as well as tumor immune microenvironment (5)(6)(7)(8). Among them, ubiquitinationmediated degradation of target protein with high selectivity is a key pathway for post-translational modification, which plays a significant role in oncogenesis and pathological mechanism (9).…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the most refractory human malignancies. F-box only proteins (FBXO) are the core components of SKP1-cullin 1-F-box E3 ubiquitin ligase, which have been reported to play crucial roles in tumor initiation and progression via ubiquitination-mediated proteasomal degradation. However, the clinical implications and biological functions of FBXOs in PDAC have not been fully clarified. Herein we perform a comprehensive analysis for the clinical values and functional roles of FBXOs in PDAC using different public databases. We found that FBXO1 (CCNF), FBXO20 (LMO7), FBXO22, FBXO28, FBXO32, and FBXO45 (designated six-FBXOs) were robustly upregulated in PDAC tissues, which predicted an adverse prognosis of PDAC patients. There was a significant correlation between the expression levels of six-FBXOs and the clinicopathological features in PDAC. The transcriptional levels of six-FBXOs were subjected to the influence of promoter methylation levels. There were more than 40% genetic alterations and mutations of six-FBXOs, which affected the clinical outcome of PDAC patients. Furthermore, the expression of six-FBXOs was associated with immune infiltrations and activated status, including B cells, CD8+ T cells, CD4+ T cells, NK cells, macrophages, and dendritic cells. The functional prediction revealed that the six-FBXOs were involved in ubiquitination-related pathways and other vital signaling pathways, such as p53, PI3K/Akt, and Hippo pathway. Therefore, six-FBXOs are the promising prognostic biomarkers or potential targets for PDAC diagnosis and treatment.

show abstract

CD58 Immunobiology at a Glance

Cited by 32 publications

References 218 publications

CD58 as a biomarker for prognosis and immune infiltration in hepatocellular carcinoma

CD58 as a biomarker for prognosis and immune infiltration in hepatocellular carcinoma

Large-scale comparison of immunoassay- and aptamer-based plasma proteomics through genetics and disease

Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma

Contact Info

Product

Resources

About